No efficacy data released yet; the stock is unlikely to move until topline results in late 2026. Monitor for any early leaks or presentations at medical conferences. The SWIFT-SC subcutaneous program adds optionality but remains early-stage.
GRFS drugs
GRFS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $8.05entry
- T+1 · 3mo ago −0.75%α −0.43% · $7.99
- T+5 · 3mo ago −3.48%α −3.43% · $7.77
- T+20 · 2mo ago −3.73%α −2.81% · $7.75
- T+60 · 14d ago +6.34%α +8.75% · $8.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3 SPARTA trial evaluating Prolastin-C in alpha-1 antitrypsin deficiency patients with emphysema. Topline results are expected by the end of 2026. This is a pipeline milestone with no financial data or efficacy readout yet.
Key Facts
- SPARTA Phase 3 trial completed last-patient-last-visit; topline results expected by end of 2026.
- Trial enrolled 345 participants across 37 sites in 16 countries.
- Evaluates two dose regimens of Prolastin-C (60 mg/kg and 120 mg/kg) vs placebo over three years.
- Primary endpoint is whole-lung CT densitometry, a sensitive measure of emphysema progression.
- Grifols also initiated SWIFT-SC Phase 3 trial for a subcutaneous alpha-1 proteinase inhibitor.
Financial Impact
No financial figures disclosed; commercial impact depends on topline results expected year-end 2026.
Risk Factors
- Topline results may fail to show statistically significant efficacy on CT densitometry endpoint.
- Even if positive, label expansion and market adoption for Prolastin-C may be limited.
- Competition from other augmentation therapies and subcutaneous formulations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341676 |
Track record
7 reports on GRFS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $8.51 to $8.69 Now $8.69 +2.12% ▲ +2.12% +2.04% vs SPY
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $8.51 to $8.69 Now $8.69 +2.12% ▲ +2.12% +2.04% vs SPY
- Aug 10, 202614w ago Press Release Neutral 4/10 Viewing Entry $8.05 to $7.77 Now $8.69 +7.95% ▼ −3.48% −3.43% vs SPY
- Jul 30, 202615w ago 6-K Neutral 2/10 Entry $8.20 to $7.83 Now $8.69 +5.98% ▼ −4.51% −8.13% vs SPY
- Jul 16, 202617w ago Press Release Neutral 4/10 Entry $7.33 to $7.54 Now $8.69 +18.55% ▲ +2.86% +4.54% vs SPY
- Jun 18, 202621w ago 6-K Neutral 3/10 Entry $7.28 to $7.39 Now $8.69 +19.37% ▲ +1.51% +3.58% vs SPY
- Mar 17, 202634w ago Press Release Bullish 7/10 Entry $8.02 to $7.60 Now $8.69 +8.35% ▼ −5.24% −2.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers